Both active substances have been available in the European Union (EU) since the late 1990s: abacavir was granted marketing approval as Ziagen in 1999, and lamivudine was granted marketing authorisation as Epivir in 1996.
Mõlemaid toimeaineid on turustatud Euroopa Liidus alates 1990ndate aastate lõpust: abakaviirile anti müügiluba Ziageni nime all 1999. aastal ja lamivudiinile Epiviri nime all 1996. aastal.